Xeris Biopharma (XERS) announced that the United States Patent and Trademark Office has issued a notice of allowance for its subsidiary Xeris Pharmaceuticals’ U.S. patent application covering XP-8121, one of its product candidates. The notice of allowance indicates that the USPTO has determined the application meets the requirements for patentability and is expected to issue as a U.S. patent following standard administrative steps. The allowed claims in this application are specific to the XP-8121 formulation. In parallel, Xeris continues to pursue additional layers of U.S. and international IP protection in the levothyroxine technology space.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XERS:
- Xeris Biopharma price target raised to $8 from $6 at Piper Sandler
- Xeris Pharmaceuticals: Strong Growth Potential and First Profitable Quarter Drive Buy Rating
- Xeris Biopharma Reports Strong Q3 2025 Financial Results
- Xeris Biopharma Reports Record Revenue Growth in Earnings Call
- Xeris Biopharma reports Q3 EPS 0c, consensus 0c